S
S. O'Brien
Researcher at University of Newcastle
Publications - 26
Citations - 1594
S. O'Brien is an academic researcher from University of Newcastle. The author has contributed to research in topics: Imatinib & Chronic myelogenous leukemia. The author has an hindex of 11, co-authored 25 publications receiving 1570 citations.
Papers
More filters
Journal ArticleDOI
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers,Andreas Hochhaus,Eric J. Feldman,John M. Goldman,Carole B. Miller,Oliver G. Ottmann,Charles A. Schiffer,Moshe Talpaz,François Guilhot,Michael W. Deininger,Thomas M. Fischer,S. O'Brien,Richard Stone,Carlo Gambacorti-Passerini,Nigel H. Russell,Jose J. Reiffers,Thomas C. Shea,Bernard Chapuis,Steven Coutre,Sante Tura,Enrica Morra,Richard A. Larson,Alan Saven,Christian Peschel,Alois Gratwohl,Franco Mandelli,Monique Ben-Am,Insa Gathmann,Renaud Capdeville,Ronald Paquette,Brian J. Druker +30 more
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
Journal ArticleDOI
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
S. O'Brien,P Meinhardt,E Bond,Joachim Beck,Bin Peng,Catherine Dutreix,Günther H. Mehring,S Milosavljev,C Huber,Renaud Capdeville,T Fischer +10 more
TL;DR: The coadministration of imatinib at steady state with 40 mg simvastatin increases the exposure (Cmax and AUCs) of simVastatin significantly (P<0.001) by two-three-fold and Caution is therefore required when administering imatinIB with CYP3A4 substrates with a narrow therapeutic window.
Journal ArticleDOI
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study
TL;DR: This analysis confirms the high rates and durability of responses to IM and further demonstrate the beneficial effect of cytogenetic and molecular responses on long-term outcomes.
Journal ArticleDOI
Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38)
Journal ArticleDOI
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
Adam R. Craig,Hagop M. Kantarjian,J. E. Cortes,D. Jones,A. Hochhaus,S. O'Brien,Mary Beth Rios,C. Zander,L. Gleich,E. P. Carroll,Oliver G. Ottmann +10 more
TL;DR: INNO-406 is an orally available, dual Abl/Lyn kinase inhibitor that is up to 55-times more potent than imatinib in Bcr-Abl cell lines.